Safeguarding access to export markets - Interpharma

A strong economic framework

Safeguarding access to export markets

Regulated access for Switzerland to the EU single market and the most important global export markets must be safeguarded.

Click on icons for more information
Created with Sketch. Created with Sketch.
A i

Bilaterals III ensures unhindered access to the European single market and puts the economic and political relationship with the EU on a solid footing. Interpharma supports this mandate for negotiations with the European Union, particularly because it gives Switzerland planning and legal certainty as a research and production location. The population also sees clear benefits in the further development of the bilateral approach: over 70% of eligible voters support the contents of Bilaterals III, according to a representative poll conducted by gfs.bern on behalf of Interpharma and other industry associations. Watch this video to see what bilateral relations mean for the research and development of innovative medicines in Switzerland, as well as the ability to export them:

Overview Agreements between Switzerland and the EU Research agreement Switzerland-UK relations

Functioning commercial relationships are vital for an export-oriented country like Switzerland. The pharmaceutical industry alone exports goods worth more than CHF 100 billion annually. Around half of this volume is exported to the European Union. Regulated and stable commercial relationships with the EU are therefore essential for the pharmaceutical industry. Yet Switzerland also needs to conclude free-trade agreements with other countries. A country-specific approach will be required, determined by the development status of the country concerned. In this way, countries with less purchasing power will also gain access to innovative medicinal products.

The pharmaceutical industry is actively concerned with the question of trade agreements. Where new agreements are concluded, compliance with minimum standards must be ensured at all times, with strong protection of intellectual property. In addition to multilateral agreements, which represent the most effective means of ensuring access to the market, industry-specific mutual recognition agreements (MRA) are also needed.

Global recognition of innovative achievements

The research-based pharmaceutical industry pursues a systematic strategy of specialisation and innovation that requires companies to make a consistently high level of investment in research and development. Long-term investment of this kind can only be economically justified in an environment with global market access that is free of discrimination and strong, enforceable protection of intellectual property rights. Central requirements for this are a functioning international trade system within the World Trade Organization (WTO) and expansion of the network of free-trade agreements with clear priorities.

Further information

About us

Interpharma, the association of Switzerland’s research-based pharmaceutical industry, was founded in Basel in 1933.

Interpharma informs the public about issues that are important to the research-based pharmaceutical industry in Switzerland, including the pharma market in Switzerland, healthcare and biomedical research.

Annual report

Information on our key figures and activities in the financial year 2023

read more

Board and Executive Management

Introducing Interpharma

read more

Vision and Mission

More about the tasks and overriding aims of Interpharma

read more


Contact us

read more


Latest information and media contacts for media representatives

read more